Metformin glycinate
/ Metformin, Actoplus Met, Avandamet, Competact, Ebymect, Efficib, Eucreas, Fortamet, Glumetza, Icandra, Invokamet, Janumet, Jentadueto, Kazano, Komboglyze, Metformin, Metformin /, Prandimet, Qternmet, Qtrilmet, Ristfor, Segluromet, Sitagliptin / Metformin, Synjardy, Trijardy, Velmetia, Vipdomet, Vokanamet, Xigduo, Zituvimet, Zomarist (metformin glycinate) is an unknown pharmaceutical. Metformin glycinate was first approved as Glucophage on 1995-03-03. It has been approved in Europe to treat type 2 diabetes mellitus.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| actoplus met | New Drug Application | 2024-06-28 |
| alogliptin and metformin hydrochloride | NDA authorized generic | 2024-02-12 |
| appformin | unapproved drug other | 2011-08-08 |
| appformin-d | unapproved drug other | 2011-08-08 |
| avandamet | New Drug Application | 2012-08-30 |
| dapagliflozin and metformin hydrochloride | NDA authorized generic | 2024-06-12 |
| fortamet | New Drug Application | 2010-03-15 |
| glipizide and metformin hydrochloride | ANDA | 2018-12-11 |
| glipizide and metformin hydrochloride glipizide and metformin hydrochloride | ANDA | 2023-10-30 |
| glipizide and metformin hcl | ANDA | 2024-10-28 |
Show 41 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
EMPAGLIFLOZIN / METFORMIN HYDROCHLORIDE, SYNJARDY, BOEHRINGER INGELHEIM | |||
| 2026-12-20 | PED | ||
| 2026-06-20 | NPP | ||
EMPAGLIFLOZIN / METFORMIN HYDROCHLORIDE, SYNJARDY XR, BOEHRINGER INGELHEIM | |||
| 2026-12-20 | PED | ||
| 2026-06-20 | M-296 | ||
LINAGLIPTIN / METFORMIN HYDROCHLORIDE, JENTADUETO, BOEHRINGER INGELHEIM | |||
| 2026-12-20 | PED | ||
| 2026-06-20 | M-295 | ||
LINAGLIPTIN / METFORMIN HYDROCHLORIDE, JENTADUETO XR, BOEHRINGER INGELHEIM | |||
| 2026-12-20 | PED | ||
| 2026-06-20 | M-295 | ||
ALOGLIPTIN BENZOATE / METFORMIN HYDROCHLORIDE, KAZANO, TAKEDA PHARMS USA | |||
| 2026-07-27 | M-300 | ||
ERTUGLIFLOZIN / METFORMIN HYDROCHLORIDE, SEGLUROMET, MSD SUB MERCK | |||
| 2024-09-17 | M-275 | ||
METFORMIN HYDROCHLORIDE / SITAGLIPTIN PHOSPHATE, JANUMET, MSD SUB MERCK | |||
| 2024-06-04 | PED | ||
| 2023-12-04 | M-187 | ||
METFORMIN HYDROCHLORIDE / SITAGLIPTIN PHOSPHATE, JANUMET XR, MSD SUB MERCK | |||
| 2024-06-04 | PED | ||
| 2023-12-04 | M-187 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Metformin Hydrochloride, Riomet Er, Sun Pharm | |||
| 9962336 | 2035-05-01 | DP | |
| Empagliflozin / Linagliptin / Metformin Hydrochloride, Trijardy Xr, Boehringer Ingelheim | |||
| 9949998 | 2034-06-11 | U-2290, U-2731 | |
| 10258637 | 2034-04-03 | U-2290, U-2731 | |
| 11090323 | 2034-04-03 | U-3192, U-3193 | |
| 11833166 | 2034-04-03 | U-3776, U-3777 | |
| 10596120 | 2032-03-07 | DP | U-2775, U-2776, U-2790, U-2792 |
| 11564886 | 2032-03-07 | DP | U-3531 |
| 10406172 | 2030-06-15 | DP | U-2733 |
| 9155705 | 2030-05-21 | DP | |
| 8551957 | 2029-10-14 | DP | U-2730 |
| 9415016 | 2029-04-02 | DP | |
| 10022379 | 2029-04-02 | U-2339, U-2732 | |
| 7579449 | 2028-08-01 | DP | |
| 7713938 | 2027-04-15 | DS, DP | |
| 8883805 | 2025-11-26 | DP | |
| 7407955 | 2025-05-02 | DS, DP | |
| Empagliflozin / Metformin Hydrochloride, Synjardy, Boehringer Ingelheim | |||
| 9949997 | 2034-05-17 | U-3532, U-3533 | |
| 11813275 | 2034-04-03 | U-3759 | |
| 10610489 | 2030-09-30 | DP | |
| Linagliptin / Metformin Hydrochloride, Jentadueto Xr, Boehringer Ingelheim | |||
| 9555001 | 2033-03-06 | DP | U-1967, U-1968 |
| 9173859 | 2027-05-04 | DP | U-1503 |
| Dapagliflozin / Metformin Hydrochloride, Xigduo Xr, Astrazeneca Ab | |||
| 9616028 | 2030-11-12 | DP | |
| 8685934 | 2030-05-26 | U-1522 | |
| 7919598 | 2029-12-16 | DP | |
| 8501698 | 2027-06-20 | DP | U-493 |
| 6515117 | 2025-10-04 | DS, DP | U-493 |
| Ertugliflozin / Metformin Hydrochloride, Segluromet, Msd Sub Merck | |||
| 9308204 | 2030-10-21 | DP | |
| 9439902 | 2030-10-21 | U-2214 | |
| 8080580 | 2030-07-13 | DS, DP | U-2214 |
| Canagliflozin / Metformin Hydrochloride, Invokamet, Janssen Pharms | |||
| 11576894 | 2030-07-06 | DP | |
| 7943582 | 2029-02-26 | DS, DP | U-493, U-2441, U-2632 |
| 8513202 | 2027-12-03 | DS, DP | U-493, U-2441, U-2632 |
| 7943788 | 2027-07-14 | DS, DP | |
| 8222219 | 2025-04-11 | U-493, U-2441, U-2632 | |
| 8785403 | 2024-07-30 | DP | |
| Linagliptin / Metformin Hydrochloride, Jentadueto, Boehringer Ingelheim | |||
| 8846695 | 2030-06-04 | U-1503 | |
| 10973827 | 2029-04-02 | DP | |
| 8673927 | 2027-05-04 | U-1503 | |
| Alogliptin Benzoate / Metformin Hydrochloride, Kazano, Takeda Pharms Usa | |||
| 8900638 | 2029-05-24 | DP | |
| 7807689 | 2028-06-27 | DS, DP | U-1337 |
| 8288539 | 2025-06-24 | DP | |
| 8173663 | 2025-03-15 | U-1338 | |
| Metformin Hydrochloride / Pioglitazone Hydrochloride, Actoplus Met, Takeda Pharms Usa | |||
| 9320714 | 2029-02-03 | DP | |
| 9101660 | 2027-01-22 | DP | |
Show 5 more
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
2814 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 147 | 231 | 494 | 310 | 224 | 1368 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 89 | 206 | 464 | 269 | 180 | 1171 |
| Healthy volunteers/patients | — | — | — | 201 | 2 | — | 2 | 12 | 217 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 19 | 22 | 33 | 51 | 56 | 170 |
| Syndrome | D013577 | — | — | 12 | 30 | 34 | 36 | 52 | 152 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 9 | 30 | 19 | 32 | 38 | 121 |
| Insulin resistance | D007333 | HP_0000855 | — | 7 | 27 | 21 | 27 | 21 | 95 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 5 | 11 | 10 | 18 | 36 | 77 |
| Gestational diabetes | D016640 | HP_0009800 | O24.4 | 3 | 6 | 18 | 12 | 25 | 60 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | 2 | 9 | 10 | 13 | 26 | 57 |
Show 173 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 12 | 9 | 2 | — | 4 | 26 |
| Adenocarcinoma | D000230 | — | — | 2 | 18 | 1 | — | 2 | 22 |
| Carcinoma | D002277 | — | C80.0 | 5 | 17 | 3 | — | 1 | 22 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 4 | 11 | 4 | — | 3 | 19 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 13 | 1 | — | 2 | 18 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 12 | 1 | — | 2 | 15 |
| Colorectal neoplasms | D015179 | — | — | 2 | 9 | 3 | — | 1 | 15 |
| Recurrence | D012008 | — | — | 2 | 4 | 2 | — | 2 | 9 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 6 | 3 | — | 2 | 9 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | — | 8 | 6 | — | 1 | 9 |
Show 85 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 7 | 11 | — | — | 4 | 20 |
| Squamous cell carcinoma | D002294 | — | — | 4 | 6 | — | — | 1 | 10 |
| Leukemia | D007938 | — | C95 | 3 | 4 | — | — | 3 | 10 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 4 | 5 | — | — | 1 | 9 |
| Melanoma | D008545 | — | — | 3 | 7 | — | — | — | 8 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 6 | — | — | — | 8 |
| Lymphoma | D008223 | — | C85.9 | 2 | 5 | — | — | — | 7 |
| Sclerosis | D012598 | — | — | 2 | 6 | — | — | — | 7 |
| Pharmacokinetics | D010599 | — | — | 5 | 1 | — | — | 1 | 7 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 1 | — | — | 4 | 6 |
Show 171 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 10 | — | — | — | 3 | 13 |
| Therapeutic equivalency | D013810 | — | — | 10 | — | — | — | 2 | 12 |
| Disease | D004194 | EFO_0000408 | R69 | 2 | — | — | — | 4 | 6 |
| Drug interactions | D004347 | — | — | 5 | — | — | — | — | 5 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 1 | — | — | — | 3 | 4 |
| Microbiota | D064307 | — | — | 1 | — | — | — | 2 | 3 |
| Fasting | D005215 | EFO_0002756 | — | 2 | — | — | — | 1 | 3 |
| Pain | D010146 | EFO_0003843 | R52 | 1 | — | — | — | 1 | 2 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | — | — | — | — | 2 |
| Lipid metabolism disorders | D052439 | — | — | 1 | — | — | — | 1 | 2 |
Show 46 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatitis | D010195 | HP_0001733 | K85 | — | — | — | — | 5 | 5 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | — | 2 | 2 |
| Disease-free survival | D018572 | EFO_0000409 | — | — | — | — | — | 2 | 2 |
| Ischemic stroke | D000083242 | — | — | — | — | — | — | 2 | 2 |
| Fertilization in vitro | D005307 | — | — | — | — | — | — | 2 | 2 |
| Essential hypertension | D000075222 | — | I10 | — | — | — | — | 2 | 2 |
| Chronic pancreatitis | D050500 | EFO_0000342 | K86.1 | — | — | — | — | 2 | 2 |
| Precocious puberty | D011629 | — | E22.8 | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
Show 79 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Metformin glycinate |
| INN | metformin glycinate |
| Description | Actoplus Met, Avandamet, Competact, Ebymect, Efficib, Eucreas, Fortamet, Glucovance, Glumetza, Icandra, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Metaglip, Prandimet, Qternmet, Qtrilmet, Ristfor, Segluromet, Synjardy, Trijardy, Velmetia, Vipdomet, Vokanamet, Xigduo, Zituvimet, Zomarist (metformin glycinate) is an unknown pharmaceutical. Metformin glycinate was first approved as Glucophage on 1995-03-03. It has been approved in Europe to treat type 2 diabetes mellitus. |
| Classification | Unknown |
| Drug class | hypoglycemics (phenformin type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 121369-64-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108299 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | YEI21W005Y (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Janumet – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 19,295 documents
View more details
Safety
Black-box Warning
Black-box warning for: Actoplus met, Alogliptin and metformin hydrochloride, Appformin, Appformin-d, Avandamet, Dapagliflozin and metformin hydrochloride, Fortamet, Glipizide and metformin hcl, Glumetza, Glyburide and metformin hydrochloride, Glyburide-metformin hydrochloride, Invokamet, Invokamet invokamet xr, Janumet, Janumet xr, Jentadueto, Jentadueto xr, Kazano, Kombiglyze, Metformin er 500 mg metformin er 750 mg, Metformin hydrochloride, Metformin hydrochloride extended-release, Metformin hydrochloride metformin hydrochloride, Metformin hydrochloride oral solution, Pioglitazole and metformin hydrochloride, Pioglitazone and metformin, Pioglitazone hydrochloride and metformin hydrochloride, Saxagliptin and metformin, Saxagliptin and metformin hydrochloride, Segluromet, Sitagliptin and metformin hydrochloride, Synjardy, Synjardy synjardy, Trijardy xr, Xigduo, Zituvimet, Zituvimet xr
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
143,228 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use